Novo Nordisk gears up for December Ozempic launch
Danish drug maker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold…
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said. New Delhi: Novo…
Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth
Bengaluru – Biocon Biologics, the biopharmaceutical arm of Biocon Ltd, is strengthening its foothold in the global insulin market while making a decisive move into the booming GLP-1 drug segment.…
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge
India’s anti-obesity drug market has grown more than fourfold in the last five years fuelled by rising instances of lifestyle diseases along with greater affordability and willingness among a section…
Novo Nordisk to phase out country’s largest insulin brand
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard…
Novo Nordisk regains membership in UK pharma body
London: Danish pharmaceutical giant Novo Nordisk has regained its membership in the UK’s pharmaceutical industry body after serving a two-year suspension for breaching a national drugmakers practice code. The Association of the British…
